FDA granted accelerated approval to Elrexfio (elranatamab-bcmm), a bispecific B-cell maturation antigen-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
An FDA advisory panel has recommended approval of Moderna’s mRNA-based flu vaccine, mFlusiva, for adults ages 50-64, and adults 65 and older, if a specific condition is met.
